PREDICT DNA and SCANDARE Study Results Unveiled
Personalis, Inc. unveiled promising new clinical data from the PREDICT DNA and SCANDARE studies at ASCO 2025.
Category: Breast
Breast
Latest
Breast
Latest
Alverno Labs Expands Practice of Ibex’s AI-Powered Cancer Diagnostics Platform
Alverno Laboratories has expanded its use of Ibex’s AI-powered cancer diagnostics platform to include breast cancer detection for patients.
Breast
Latest
The Breast Cancer Index Test is Guiding Hormone Therapy Decisions
BCI testing is reshaping treatment decisions for early-stage HR+ breast cancer patients by helping guide endocrine therapy choices.
Exai Bio’s RNA-Based Liquid Biopsy Platform Detects Early Stage Breast Cancer Accurately
Exai Bio’s liquid biopsy platform can detect breast cancer at the earliest stages and the smallest tumor sizes using a standard blood sample.Â
Read More
Reveal Genomics Details Success of Liquid Biopsy Test for Metastatic Breast Cancer
DNADX utilizes sequencing DNA data from tumor tissue or plasma circulating tumor DNA to classify breast cancer into four subtypes or clusters.
Read More
Digital Morphology Solution Predicts Breast Cancer Recurrence
PreciseBreast, an AI-powered digital morphology tool, has a fast turnaround time and is cost-effective compared to gene expression tests.
Read More
Universal Hereditary Cancer Genetic Testing Breast Cancer Improves Patient Outcomes
Invitae announced the results of its study on universal hereditary cancer genetic testing in breast cancer patients in a rural population.
Read More
Biocartis Expands APIS Assay Technologies Collab to Commercialize Mutations Kit
Biocartis and APIS Assay Technologies are expanding their collaboration to include the commercialization of the APIS ESR1 Mutations Kit.
Read More
Study Finds Reductions in Breast Cancer Screening During Pandemic
The findings suggest the need for continued monitoring of access to breast cancer screening and early diagnosis services.
Read More
Ibex Launches Galen Breast HER2 to Support Breast Cancer Biomarker Scoring
Ibex launched an AI-powered solution that aids pathologists in setting a higher standard for accurate HER2 scoring in breast cancer patients.
Read More
How a Computational Model Predicts Genetic Risk for Breast Cancer
This computational model makes it possible to predict the genetic risk of developing breast cancer based on genetic profiles.Â
Read More
Breast Cancer Overdiagnosis Common Among Older Women
New findings suggest that overdiagnosis may be common among older women who are diagnosed with breast cancer after screening.
Read More
Devyser Debuts 2 Genetic Test Kits for Hereditary Cancer
Devyser LynchFAP and Devyser BRCA PALB2 genetic test kits offer efficient, targeted analysis of genes associated with increased cancer risk.
Read More
Exai Bio Expands RNA-based Breast Cancer Liquid Biopsy Platform through Collaboration
Exai Bio is collaborating with Quantum Leap Healthcare Collaborative to broaden the use of its novel, RNA-based liquid biopsy platform.
Read More
DCIS Risk Assessment Test Gets CMS Advanced Diagnostic Laboratory Test Status Approval
The Centers for Medicare & Medicaid Services approved Advanced Diagnostic Laboratory Test status for PreludeDx’s DCISionRT test.
Read More
Medicare Extends Coverage of Natera’s Signatera MRD Test to Breast Cancer
Natera’s Signatera MRD test has met coverage requirements for adjuvant and recurrence monitoring in patients with breast cancer.
Read More
PreciseDx AI-Enabled Breast Diagnostic Gets Approval from NY State
PreciseDx announced that the NYSDOH approved the PDxBr, an LDT designed to enrich breast cancer grading and improve risk categorization.
Read More
AstraZeneca, Ibex Collaborate on Novel AI-Powered HER2 Scoring Product
The companies are collaborating on a product to aid pathologists with an accurate assessment of HER2 IHC scoring in breast cancer patients.Â
Read More